Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Pancreatic Cancer Vaccine in advanced pancreatic cancer
NCT03136406Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2017
- Primary completion
- Nov 2017
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, NK-92, ETBX-011, GI-4000 in pancreatic cancer (PC), sponsored by ImmunityBio, Inc.. Started Aug 2017; status: terminated.
02
Drugs
nogapendekin alfa inbakiceptNK-92ETBX-011GI-4000
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03136406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136406.